Publications by authors named "Fenge Yang"
Background: The coronavirus disease 2019 (COVID-19)-associated mortality rate of hemophilia patients is similar to that of the general population, but the risk of hospitalization and bleeding is higher. However, the specific impact of this infection on hemophilia patients remains unknown. We aimed to investigate the impact of the pandemic on the infection susceptibility, symptoms, drug use, and social intercourse of patients with hemophilia.
View Article and Find Full Text PDFArticle Synopsis
- Sovleplenib, a new SYK inhibitor, showed effective results and safety in treating patients with chronic primary immune thrombocytopenia in a phase 3 trial conducted in China.
- The trial involved 188 participants who were given either sovleplenib or a placebo, with results showing a significant durable response rate of 48% for sovleplenib compared to 0% for the placebo group.
- The study demonstrated a faster median time to response of 8 days for patients on sovleplenib versus 30 days for those receiving placebo, highlighting its potential efficacy in this condition.
Article Synopsis
- - A 54-year-old man experienced severe bleeding after a rectal polypectomy that several treatments failed to control, pointing to a rare case of coagulation disorders post-surgery.
- - Tests revealed an uncorrectable prolonged activated partial thromboplastin time (APTT) without signs of autoimmune disease, leading doctors to suspect nonspecific antibodies.
- - After treating the patient with cyclophosphamide and glucocorticoids, APTT normalized and bleeding ceased, resulting in a diagnosis of prolonged APTT due to monoclonal gammopathy of undetermined significance (MGUS), which is a rare condition associated with coagulopathy.
Introduction: Omfiloctocog alfa, the first China-developed recombinant factor VIII (FVIII), demonstrated efficacy and safety of prophylaxis in previously treated patients (PTPs) aged ≥12 years with severe hemophilia A in China.
Aims: To investigate efficacy, safety and pharmacokinetics (PK) of omfiloctocog alfa in pediatric PTPs with severe hemophilia A in China.
Methods: PTPs (>50 exposure days [ED] for Chinese patients aged <6 years; >150 EDs for patients aged 6-12 years) were treated with omfiloctocog alfa at 25-50 IU/kg every other day or three times per week for 24 weeks.
Introduction: SCT800 is a recombinant human B-domain-deleted coagulation factor VIII (BDDrFVIII) developed in China.
Aim: To evaluate the repeat pharmacokinetics (PKs), efficacy, and safety of SCT800 in previously treated Chinese adolescent and adult patients with severe haemophilia A.
Methods: A phase III, multicentre, prospective, open-label, single-arm trial was conducted at 12 medical centres.
Antihemophilic factor (recombinant) (rAHF; ADVATE; Baxalta US Inc., a Takeda company, Lexington, MA, USA) is indicated for the treatment and prevention of bleeding in patients with hemophilia A. We aimed to assess the safety and efficacy of standard prophylaxis versus on-demand treatment with rAHF in previously treated Chinese patients with severe/moderately severe hemophilia A.
View Article and Find Full Text PDFPurpose: Hemophilia care in China is characterized by widespread use of on-demand regimens and low-dose prophylaxis. With a limited number of approved recombinant factor VIII (FVIII) products, the incidence of arthropathy and disability in hemophilia patients remains high in China. The purpose of this trial was to evaluate the safety and efficacy of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients from China with severe hemophilia A across all age groups.
View Article and Find Full Text PDFPrimary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition.
View Article and Find Full Text PDF[Expression of Hydrodynamic Injection-mediated PD-L1 in Myeloablative Conditioning Mouse Model].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
October 2015
Objective: To establish the mouse model for the expression of PD-L1 by hydrodynamic injection and to study the effects of myeloablative conditioning on hydrodynamic injection-mediated PD-L1 expression.
Methods: Plasmid amplification, hydrodynamic injection, collagenase perfusion, real time PCR, ELISA and flow cytometry were applied to test the expression and function of PD-L1. Also, animal models were set up to test the effects of chemical or radiactive myeloablative conditioning on hydrodynamic injection-mediated PD-L1 expression.
[Total knee arthroplasty for the treatment of hemophilic arthropathy of the knee].
Zhongguo Gu Shang
December 2011
Objective: To study the efficacy of total knee anhmplasty (TKA) for the treatment of hemophilic knee arthropathy, and to explore the operative characteristics, the selection of prothesis, the effectiveness and safety of clotting factor replacement treatment.
Methods: From January 2008 to June 2010, 10 patients (12 knees)with hemophilic anhropathv underwent TKA. The average age was 33.